JUBLPHARMA (Jubilant Pharmova Ltd.): Regulatory Approval
Jubilant Pharmova has told the exchange that the US Food and Drug Administration has approved Line 3 at its contract manufacturing facility in Spokane, in the United States, according to a filing on the NSE published at 00:49 on 23 Aug. The intimation arrived over a weekend: the evidence pack's price data runs only to 2026-08-21, and the quoted change of 0.0% reflects a stock that has not yet traded on the news, not a market verdict on it.
Strota's tracker files this under Regulatory Approval and tags the event type with a bullish bias. That tag is a classification, not a forecast. The pack behind this article carries no historical reaction base rate for approvals — the figure that would normally say how stocks in general have behaved after events like this — so no such number can honestly be quoted here.
The stock the approval lands on has been weak. Jubilant Pharmova closed at Rs 880.35, down 25.7% from its 52-week high of Rs 1184.8 and 12.0% above its 52-week low of Rs 786.05. It trades below both its 50-day and 200-day averages, with a 14-day relative strength index of 35.7, a reading closer to the oversold end of the scale. Recent returns tell the same story: up 1.6% over a week, but down 9.3% over a month and 16.4% over a year. Valuation stands at a price-to-earnings ratio of 39.54 and a price-to-book of 1.96.
What the data establishes is the approval itself and a beaten-down chart beneath it. What it does not establish is any measured market reaction to the filing — that can only be observed once the stock trades again.
The catalyst
Jubilant Pharmova Limited has informed the Exchange about General Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A (filing · NSE)
What the data shows after this event
Strota has not yet measured a reliable next-session base rate for Regulatory Approval events on enough history.
JUBLPHARMA right now
trading +0.00% on the day; P/E 39.54; RSI 35.7. Full JUBLPHARMA analysis →
Sources
- Jubilant Pharmova Limited has informed the Exchange about General Updates-USFDA Approval for Line 3, Contract manufacturing facility, Spokane, U.S.A — NSE
- Jubilant Pharmova subsidiary to appeal Rs 53.37 Cr tax disallowance — scanx.trade
- Jubilant Pharmova Q4 profit declines 21 pc at Rs 119.3 cr — pharma.economictimes.indiatimes.com
- Jubilant Pharmova Q4 profit declines on margin pressure; revenue rises 19% — CNBC TV18
- Jubilant Pharmova Ltd. Share Price Today - Jubilant Pharmova Ltd. Stock Price Live NSE/BSE — CNBC TV18
Keep digging
- JUBLPHARMA — full smart-money page: F&O positioning, deals, insider filings and option chain in one place.
- Today's screens: every stock matching the same setups (buildups, breakouts, volume shockers).
- Newsroom: the other stocks in play this session.